Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioGaia, Audiocast with teleconference, Q2'24

By Inderes7/23/2024, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:01 - 06:28

Hi, this is Theresa Agnew, CEO of BioGaia. Theresa, Alexander, and I are here to share our Q2 results. For Q2, our sales were 384 million SEK, which is a growth of 22%. That was mainly driven by growth in the APAC region as well as our Americas region. Sales in Europe, the Middle East, and Africa increased by 7%. Sales in Asia Pacific increased by 49% and in the Americas by 22%. We did have some orders affected due to quarterly variations in specific areas, particularly in China and Brazil. Our EBIT was 134 million MSEK, which is a growth of 42%, and our EBIT margin is 35%. Earlier in the month of June, we announced that we are taking our business direct in Australia and New Zealand. This is really exciting for us. It is one of our future investments. Australia is actually the 12th largest probiotics market in the world, and we have a really big opportunity to grow in both Australia and New Zealand. These are both markets where consumers understand probiotics, and we are introducing our probiotics drops initially, followed by an expansion of our other probiotic products in the future through the pharmacy and grocery channels in Australia and New Zealand. It's a big opportunity for us in terms of taking our business direct. And as you know, we have been successful in our other direct businesses. Previously, we were directly present in six markets. So now that makes it eight markets. Our direct business typically accounts for around 30% of our sales. So we anticipate this will continue to grow, as we've taken Australia and New Zealand direct now. Also on the news front, in early July we won our arbitration with our former Italian distributor. And we have recently, just last week, signed a long-term contract with our sub-distributor, Recordati, which is a pharmaceutical company in Italy, Spain, Portugal, and a number of other markets, so they will now be our exclusive distributor of probiotics in Italy, as well as in Spain and Portugal. As you know, over the past couple of quarters, we have been discussing future investments in our business to continue our growth. So we are ramping up our investments. In the second half of this year, we are projecting 75 to 85 million in costs, on top of our normal operating expenses. Some of those investments will be in marketing and sales activities. Specifically, we will focus on the US with a sales force that will be marketing and selling our probiotics products. As we mentioned, we are launching our direct business in Australia and New Zealand, which presents another investment opportunity for us. We will also be launching our first global advertising campaign and preparing for that launch. That will be coming up in the near term. We are also investing in new products in R&D, and in clinical studies for the future. So these are just some of the investments that we will be making to drive our continued growth. Some of the launch events and other activities in the quarter. Through our Pharmabest distributor in Italy, we launched our BioGaia Protectis drops with vitamin D, and in the UK, which is one of our direct markets, we launched our BioGaia Prodentis lozenges. As we've discussed before, Prodentis is one of the brands we are continuing to invest in. We've done extremely well in Japan, the US, and Canada. And now we are placing even more emphasis on products in the UK. As I mentioned in the overall introduction, we have announced our own distribution in Australia and New Zealand, and also announced our long-term agreement with Recordati in the Italian market. As previously mentioned, our sales increased by 22%. Our pediatric sales increased by 32%, mainly due to increased sales of our Protectis drops and an overall increase in sales across all regions, especially in markets such as China, Brazil, and Canada. For the quarter, our adult sales decreased by 6% due to decreased sales of our Prodentis tablets, mainly in South Africa, Belgium, and Japan. However, this is due to quarterly variations for individual orders. As you can see, for the year to date, our overall pediatric growth is at 11% and our overall adult health growth is at 10%. Thus, our pediatric business accounts for about 79% of our total business. In terms of the regions, as I said earlier. EMEA sales increased by 7%. This increase was primarily in Germany, Spain, and Turkey. In the Asia Pacific, our sales increased by 49%. This was mainly in China, South Korea, and Vietnam. Again, our sales were positively impacted by quarterly variations, and in the Americas, our sales grew by 22%, primarily in the US, Canada, and Brazil. Again, our sales for the quarter were positively influenced by quarterly variations, specifically in Brazil. But as you can also see, our year-to-date growth in EMEA is 10%, in Asia Pacific is 25%, and in the Americas is 3% for a total year-to-date growth of 11%. I will now hand over to Alex to discuss the financials in more detail.

Alexander Kotsinas
06:28 - 11:12

Thank you, Theresa. Let's summarize the quarter: we had revenues of 384 million, which was a growth of 22%. Our operating profit was 135 million, reflecting a growth of 42%. And the margin was 35%, compared to 30% one year ago. Earnings per share were at 1.10, and operating cash flow was 119 million. <incomplete/> Let's examine the sales bridge. We can observe that in both the quarter and the year to date. There's essentially no currency effect. It's very minimal. Thus, our entire growth essentially stems from organic growth. We move on to the gross margin. We have a total gross margin in the quarter of 74% versus 72% in the same quarter last year. For pediatrics, the margin improved from 74% to 77%, and in adult health, it decreased from 67% to 61%. Now, the main reason for the decreasing adult health margin is mixed effects. We have been selling more relatively expensive items, which is a product where we have a slightly lower margin compared to our protective tablets. So when we have a higher percentage of sales in adult health, the margin is getting lower here. And that is the main explanation for the lower margins both in the quarter and year to date. Moving on to the operating expenses. Our total expenses increased by 13%. Sales and marketing costs increased by 23%, mainly due to the increased costs in the subsidiaries that we have and the investments we are making in those subsidiaries. In terms of R&D, costs decreased from 38.8 million to 26 million, a decrease of 31%. This is mainly due to some timing and prioritization effects of the clinical studies. The cost did increase compared to the quarter previous to this one. In terms of administrative costs, they declined by 49%. This is due to a reverse allowance accrual that we had for the litigation fees in connection with the termination of the distribution agreement in Italy. And that had a positive effect on the cost. There was a negative cost, so to speak, in the quarter. And therefore we have such low costs here. And then we have the last line in opex is the other opex. That was -5.8 million versus +8.5 million. And that is due to what we have had in the quarter this year. We have experienced exchange losses. And the same quarter last year we had exchange rate gains. So all in all, the total opex was 149 million versus 131 million one year ago. <b/r> If we then summarize and look at the profit and loss, we see that we have sales of 384 million, a gross margin of 74%, and an operating expense level of 149 million, leading to an EBIT of 135 million. And then the EBIT or operating profit then increased by 42% in this quarter compared to one year ago. If we look at the margin in percent, we have a margin of 35% versus 30% a year ago. And year to date, we have a margin of 37% versus 36% in the same period last year. Moving over to the cash flow. Cash flow from operating activities increased by 14% to 119 million. The increase is mainly due to a higher operating profit despite the negative change in working capital. Cash flow from financing activities went from 296 million to 699 million. This is due to the increase in higher dividends paid this year. So in total, we paid dividends of 697 million versus 293 million in the same period last year, which leads to a cash flow for the period of 582 million versus 216 million previously. And therefore we have cash at the end of the period of 1 billion and eight sick. So with that, I hand over to Theresa for some concluding remarks.

Theresa Agnew
11:13 - 13:24

So, as we've settled the arbitration with our former Italian distributor, Noos, we have now started our new contract with Recordati for the Italian market. As we stated, our total sales increased by 22% in EMEA, specifically a 7% increase in sales in both the pediatric and adult health segments. Sales increased mainly in Germany, Spain, and Turkey. Asia Pacific continues its solid growth at 49% and was driven by higher sales in the pediatric segment, mainly in China, South Korea, and Vietnam, with sales for the quarter in Asia-Pacific impacted by quarterly variations in orders, particularly in China. Americas sales increased by 22%, mainly due to increased sales in both pediatric and adult health products, with significant growth in the US, Canada, and Brazil. Once again, sales for the quarter were positively impacted by variations, specifically in Brazil. As Alexander said, our operating expenses increased by 13%. Our EBIT margin is 35%. And as I described, we have been discussing over the last couple of quarters that we would be ramping up investments and making targeted investments. So, we will continue doing that and strive for continued growth. We are projecting our costs at 75 to 85 million SEK in the second half on top of our normal operating expenses. And I did talk a little bit about where some of that focus would be, such as in the US and Canada, in Australia and New Zealand, in a global advertising campaign that we will be starting at some point, as well as investments in our new direct businesses in Australia and New Zealand, and of course, continuing investment in our existing direct businesses to drive growth. So, that is the overall summary for Q2 as well as year to date. And we can now open it up for questions.

Operator
13:30 - 13:52

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Matthias Blom from Handelsbanken. Please go ahead.

Unknown 1
13:54 - 14:43

Yes. Good morning. A couple of questions, please. Firstly, on the OPEX expansion of 75 to 85 million SEK. So, what portion of that will be internal versus external costs? I'm trying to get a sense of how easy it will be for you to navigate these cost items, assuming the initiative does not translate into higher growth than anticipated. They spoke about the salesforce in the US, so perhaps a bit more on the nature of these costs. Secondly, is there a way for you to help us think about what magnitude of extra sales would be required for you to see that this investment is a wise one? Organic sales growth has historically been high for this company, often in excess of 15% for various time periods, so any insights on that would also be appreciated.

Theresa Agnew
14:44 - 18:34

Sure. So, just a little bit more on the nature of the costs. As I mentioned, we will be investing in the US by establishing a sales force that calls on healthcare professionals. Um, so that is something that we are starting. Obviously, when you launch a sales force, it takes time to then see the overall growth from a sales organization. But we will also be starting some additional marketing over the coming months. Not immediately. However, we will be launching additional marketing in the US as well as Canada and some of the other direct businesses. And so we will be continuing those efforts. Those are external costs because they're related to media. It will be external facing to consumers as well as healthcare professionals in terms of marketing costs. We will also be investing, as I said, in the Australia and New Zealand business. Some of those costs will be internal because it is setting up the business, looking at things like infrastructure, ERP systems, and third-party logistics, just as we would do with any direct business that we would start up. However, there are also external costs involved, as we are very pleased to announce that we have started shipping products to customers. Customers in Australia will be in the pharmacy channel and also in the grocery store channel. And so, the costs that we have there will include customer marketing and retail, consumer marketing, and healthcare professional marketing. Just as with any direct business, there will be a percentage of internal costs to set up the business, as well as external facing costs. Once we have the products distributed. So, you know, we are now in the process of starting to ship the products to retailers. It will take time. It usually takes, oh, I would say 4 to 8 weeks depending on the retailer to get products distributed. It will take some time to actually start seeing sales in the market. But there is going to be some cost for us, of course, both internal and external. And then there will be some other internal costs in terms of clinical studies that we're conducting for new products. There will be some internal costs around product development. Uh, for our future products. Uh, we will be able to announce some new products coming up over the course of the next year. Uh, so I won't give specific timing on that, but we will be launching some new products over the course of the next year, so hopefully that gives you a little description of the types of costs. We won't share the exact amounts, of course, but that gives you the nature of the cost. Uh, as your question was. And then in terms of sales growth expected, you know, we do not give guidance around sales growth, but we will be making strategic investments and we will be monitoring growth associated with our investment expectations. Uh, so we will be monitoring this on an ongoing basis. We have KPIs around this. Um, so we are doing this to drive penetration of our brand. We are doing this to drive awareness of sales into the future of our brand in select targeted markets where we are making these strategic investments. Although we won't share specific guidance around sales, we do anticipate continued growth for the products that we will be marketing.

Unknown 1
18:36 - 19:16

Please follow up with your questions. Firstly, can you help us understand the timeframe you think is reasonable to expect before this monitoring of the investment shows results? Is it reasonable to expect results within a quarter, a year, or perhaps another duration? Secondly, what gives you confidence that this will translate into higher growth? Have you already experienced, given your brief time here, any smaller-scale investments that have translated into higher growth? Thank you very much.

Theresa Agnew
19:17 - 20:53

Yes, that is a good question. The timeframe for monitoring will be on a quarterly basis as well as longer term. Some investments, such as those in R&D and sales forces, are more long-term, while others, like marketing and customer marketing efforts, are shorter-term. We will be monitoring both short-term and long-term effects. Regarding confidence in growth, we have strong confidence in the investments we're making. For instance, after increasing our advertising and marketing in our direct markets, we have seen increased sales. For example, in the US, we have had record months on Amazon in the past few months, and we have increased our marketing investments in specific areas there. Our approach is to test initiatives and then scale them more broadly. We have been testing some of the increased investments, and are now looking at scaling some of these initiatives. In terms of salesforce, many of our partners around the world have their own sales forces. They have commercial organizations that liaise with pediatricians, healthcare professionals, and pharmacists, among others. There is a lot of compelling evidence supporting our investments, which we've also observed through our partners. I hope that answers your question.

Unknown 2
20:54 - 20:54

Perfect.

Operator
21:00 - 21:06

The next question is from Matthias Watson from Seb. Please go ahead.

Unknown 3
21:09 - 21:41

Good morning. I have a follow-up regarding the extra costs you have announced. You mentioned an additional 75 to 85 million in operating expenses in H2. Is this compared to last year, or what is the norm for operating expenses in your view? Additionally, I would like to understand the extent to which these extra costs will persist in the coming years. An approximate breakdown between short-term and long-term investments would be very helpful. That's the first one.

Unknown 2
21:43 - 21:44

Okay.

Theresa Agnew
21:44 - 22:30

So just in terms of the 75 to 85 million. So we're looking at that. We're talking about that for the second half of this year. Um, we won't share what additional investments will be beyond that at this point. You know, we will obviously be evaluating investments, looking at results and so forth. So we'll share more as that progresses. Um, we won't share specifics around our normal operating costs. Just know that this is on top of our normal operating costs because our operating costs are quite extensive from what we were talking about in terms of internal costs as well as external costs. Uh, so hopefully that gives you a little bit more guidance.

Unknown 4
22:32 - 22:32

Okay.

Unknown 3
22:33 - 22:53

Then I was wondering about APAC—very strong again. And you flagged some extra elements were built in China. And then I wonder about the magnitude of this. And also I have the corresponding question then regarding Brazil. That's the second one.

Theresa Agnew
22:55 - 23:54

Okay. So in terms of China, they've had to build inventory for some events that are coming up. So they have some significant events for the third quarter. Which is why they wanted to build up more inventory for the events, the congresses, online e-commerce events, as well as they're launching our new packaging design. So this is something that is a quarterly fluctuation. In terms of preparing for these events in Brazil. Similarly, in terms of preparing for events but different types of events. Um, so, you know, they have been launching our Easy Dropper. That seems to be going well based on the feedback that we've gotten from them. That's our Protectis Easy Dropper. So they are continuing to prepare for their own events in Q3.

Unknown 4
23:56 - 23:57

Sounds good.

Unknown 3
23:57 - 24:25

And then the last one, I mean, you started the year now with 11% constant exchange rate growth, which is strong. So maybe a little bit on what you expect here for the full year. Do you expect this rate to continue or is that a very cautious way of looking at things given these extra investments that could convert to sales towards the end of the year, or just some thoughts around how we should think about it. That's the last one.

Unknown 2
24:26 - 24:26

Yeah.

Theresa Agnew
24:27 - 25:26

In terms of some of the additional costs, we're looking at continuing our growth, but some of those will not have an immediate effect. So, some of these are going to be investments that we'll see returns on over the course of the year. Of the next year, you know, from this point. Right. So, we don’t give particular guidance. We think the current strong performance at 11%. We hope to continue our growth, where we have been, and also hope that these future investments will continue to drive growth moving forward above market expectations. So, that's always our goal, to grow above the market. But we don’t know the exact timeframe and we don’t give guidance. We know that some of these investments will start to see a return over the course of the next year.

Unknown 4
25:28 - 25:29

Thanks for all the answers.

Operator
25:36 - 25:42

The next question comes from Christopher Lederberg from Carnegie Investment Bank. Please go ahead.

Unknown 2
25:44 - 25:44

Yeah. Thank you.

Unknown 3
25:44 - 25:45

Good morning.

Unknown 5
25:45 - 26:09

I have a question related to the extra cost. So, based on what you say, it seems you will have higher costs also going forward. Should we expect now that operating costs will be lower in 2025 versus 2024? Or will they continue to increase or be flat? If you could help with that.

Theresa Agnew
26:11 - 27:07

Yeah. Well, we're going to be looking at the investments that we're making. As I was saying, on a quarterly, half-yearly, and yearly basis. So, we're not signaling right now what the costs will be moving forward. We want to see some of the results over the course of the next year. So, we’ll be able to share more on that in the future. You know, as we evaluate and look at the investment potential and other things that we will be investing in. But, these are very targeted strategic investments in very particular markets where we see opportunities for growth. We aren't able to signal what the costs will be going forward. But know that as our investments prove successful, we will want to continue to invest to grow the business.

Unknown 5
27:09 - 27:41

Okay, that’s helpful, but at the same time, the report stresses that you're committed to the longer-term 34% EBIT margin target. So, as you're monitoring this and want to see higher sales from the investments, are you aiming to be back at a 34% EBIT margin in 2025? Would you accept that it might take maybe a year longer?

Theresa Agnew
27:43 - 28:20

So, we don't know yet in terms of the length of time, because we'll continue to look at the investments over time. But we are committed to our long-term target. It is a long-term target for us, but we want to continue to invest in the business, to make sure that we have a very healthy business and the things we are investing in, such as brand building, awareness, penetration of our products, R&D, innovation, and taking businesses direct. These are things that we feel confident in that will grow our business for the future.

Unknown 5
28:25 - 28:42

Okay. And my final question, when it comes to the timing of individual orders, there seem to have been both positive and negative effects. Is it fair to assume that this, on the whole group, has been a positive effect this quarter?

Theresa Agnew
28:43 - 29:10

Yes. In terms of this quarter, Q2, the growth of 22% has been positively affected by these order variations. So, you know, that is something in China and Brazil, and some other markets, where they have been preparing for events coming up in Q3. So, these are quarterly variations due to orders.

Unknown 5
29:11 - 29:24

Excellent. Just one final question. You mentioned the new packaging design in China. Is that a country-specific thing for China or something that you will aim to do on a global scale as well?

Theresa Agnew
29:25 - 30:04

So, we are aiming to change our packaging globally, but each market will roll out at a different time. So, we have already changed our packaging in Sweden. <bre /> The BioGaia packaging has been changed in Sweden, and now we are starting to roll this out in other markets. So, each market, depending on regulatory timing because you have to do all your registrations and so forth, will be a little bit different. So, it will take us really over the next couple of years to really roll out the packaging design change across the world.

Unknown 2
30:07 - 30:07

Okay.

Unknown 5
30:08 - 30:08

Thank you.

Theresa Agnew
30:10 - 30:11

You're welcome.

Operator
30:16 - 30:22

The next question comes from Matthias Blom from Handelsbanken. Please go ahead.

Unknown 1
30:24 - 31:14

Yeah. Two follow-ups, please. So, on the new strain BDL 47, it's clear from reading the recent publication that the hypothesis is that the strain will boost growth and activity of bacteria. Can you help me understand how you think this could translate into clinical benefit and human trials? Faster impact on reduction of crying time, or rather an even higher response rate, if I use colic as one example. So, maybe help me understand how this could manifest. And then secondly, coming back to this OPEX expansion, but maybe from a different angle, do you think you could have continued healthy growth without these investments, or is it rather the case that without these investments, the company was, to some extent, running out the cadence of the current growth? Thank you so much. Yeah.

Theresa Agnew
31:14 - 33:09

So, the first question on BGL 47. This is a new patented strain for us. It's a Bifidobacterium, so different than our usual bacteria. What we are looking at is the synergistic effect. If we were to launch a product that would contain both of these strains, then it would be a patented product for the future, given that the BGL 47 is a new strain. It's a little bit different in that Bifidobacteria are not necessarily as effective for colic. So there are different things that each strain is indicated for. This is something that we're looking at for overall gut health. Think of it as a healthy start for a child in terms of their overall gut and gut balance. And combining our two strains. We're looking to see these positive benefits for the future. So it's still being studied. Obviously when there's science involved, you can't promise anything. It's just something that's really interesting, that we're looking at, and then in terms of the overall growth question, I'm confident that BioGaia would continue to grow, even without these additional investments. These additional investments are being made because we want to continue that growth trajectory over time, and we want to drive even more penetration and awareness of our brand, both with healthcare professionals as well as consumers. Doing things like a global advertising campaign can be a real benefit to a brand in terms of building brand awareness, benefits of the brand, and positioning of our overall bio brand.

Unknown 1
33:11 - 33:12

That's very clear. Thank, you so much.

Operator
33:17 - 33:24

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Theresa Agnew
33:26 - 33:35

I want to thank everyone for listening in and thank you for the very good questions. And we look forward to speaking with you next quarter. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…